摘要
目的探讨奥氮平在首发精神分裂症的儿童青少年患者中的治疗效果和安全性。方法选取儿童青少年首发精神分裂症的患者80例,随机地分为研究组(n=40)和对照组(n=40),对研究组的患者给予奥氮平进行治疗,对照组的患者给予利培酮进行治疗。比较两组患者的治疗有效率。采用阳性和阴性症状量表和副反应量表对两组患者在治疗前和治疗后的第1、2、6、8周进行评定,并且比较两组的评定结果。结果两组的治疗总有效率差异无统计学意义(P>0.05),在治疗后的第1、2周,研究组患者的PANSS评分总分显著低于对照组(P<0.05),对照组患者的静坐不能和震颤的不良反应发生率显著高于研究组(P<0.05),其余不良反应两组之间差异无统计学意义,研究组患者的体重增加值显著高于对照组(P<0.05)。结论奥氮平是一种起效快、疗效显著的治疗儿童青少年精神分裂症的药物,具有较好的安全性,但是奥氮平能够增加患者的体重,对于应用于儿童青少年精神分裂症患者需要慎重考虑。
Objective To explore the effect and safety of olanzapine in the child and adolescent patients with first-episode schizophrenia. Methods 80 child and adolescent patients with first-episode schizophrenia were selected and randomly divided into the study group ( n = 40 ) and the control group ( n = 40 ). The patients of the study group were given olanzapine and the patients of the control group were given risperidone. The treatment effect of the 2 groups were compared. Using positive and negative symptoms scale (PANSS) and adverse event scale (TESS) before treatment and after treatment in patients with two groups of 1, 2, 6, 8 weeks of assess. Results Study group and control group total effective rate with no statistically significant difference ( P〉0.05 ), 1, 2 weeks after treatment, study group of pa- tients with total scores of PANSS score was significantly lower than control group (P 〈 0.05 ), the control group patients akathisia and tremor had a significantly higher incidence of adverse reactions observed group (P〈0.05), the rest of the adverse reactions has no statistically significant difference between the two groups. Children with weight of the added value is significantly higher than control group (P〈0.05) . Conclusion Olanzapine is a kind of effective fast, curative effect is distinct, the treatment of child and adolescent schizophrenia drug, but olanzapine can increase the weight of the patients, for application in child and adolescent patients with schizophrenia need careful consideration.
出处
《国际精神病学杂志》
2016年第2期269-271,共3页
Journal Of International Psychiatry
关键词
奥氮平
利培酮
儿童青少年
精神分裂症
Olanzapine
Risperidone
Child and adolescent
Schizophrenia